MedPath

Roivant Acquires Mosliciguat from Bayer for Pulmonary Hypertension Treatment

• Roivant Sciences has acquired mosliciguat, an experimental drug, from Bayer to develop as a treatment for pulmonary hypertension. • Mosliciguat targets specific types of pulmonary hypertension, addressing high blood pressure in lung arteries and heart damage. • This acquisition expands Roivant's pipeline in pulmonary disease and represents Bayer's strategic divestment of the drug.

Roivant Sciences has acquired mosliciguat, an experimental drug, from Bayer, aiming to develop it as a treatment for specific types of pulmonary hypertension. Pulmonary hypertension is a serious condition characterized by high blood pressure in the arteries of the lungs, leading to damage to the heart.

Acquisition Details

The acquisition allows Roivant to expand its pipeline in pulmonary disease. Mosliciguat, the drug acquired, is an experimental therapy that Bayer was developing. The financial terms of the deal were not disclosed.

About Mosliciguat

Mosliciguat is intended to treat pulmonary hypertension, a condition where high blood pressure in the lung arteries causes damage to the heart. The drug has undergone some initial development by Bayer, and Roivant plans to continue its development for specific subtypes of pulmonary hypertension. Further details on the mechanism of action and previous trial data were not disclosed in the announcement.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development

Molecular Partners and Orano Med have announced an expanded partnership to develop Targeted Alpha Radio-Therapies for cancer, aiming to enter a first-in-human study for Radio-DARPin MP0712 against DLL3 by 2025 and co-develop a program targeting Mesothelin.

AI-Driven Discovery Unveils Cancer Therapy Breakthrough

Rakovina Therapeutics Inc. has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments, potentially reshaping oncology research.

FDA Approves BridgeBio's Drug for Rare Heart Condition, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The FDA has approved BridgeBio's drug for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and often fatal heart condition.
This approval marks a significant advancement in treating ATTR-CM, offering a new therapeutic option for patients with this disease.

HIV Vaccine Shows Promise in Clinical Trials, Offering Potential Cure

A novel HIV vaccine, administered post-infection, has demonstrated promising results in clinical trials, suggesting a potential curative approach to HIV infection.
The Chinese pharmaceutical industry is experiencing rapid growth, with 113 innovative drugs approved since 2021, marking a significant increase in drug development.

Zepbound Demonstrates Superior Weight Loss Over Wegovy; FDA Actions Advance Lung Cancer and Psoriatic Arthritis Therapies

Eli Lilly's Zepbound showed a 47% greater relative weight loss compared to Novo Nordisk’s Wegovy in a head-to-head obesity study.
Merck's sacituzumab tirumotecan (Sac-TMT) received FDA Breakthrough Therapy designation for advanced NSCLC with EGFR mutations.

Merck Licenses Cancer Drug from LaNova, Tune Therapeutics Advances HBV Therapy, and Amgen Defends Obesity Drug

Merck will license a new cancer drug from LaNova Medicines for $588 million upfront, potentially reaching $2.7 billion in milestone payments, to bolster its oncology portfolio.
Tune Therapeutics is set to initiate human trials in New Zealand for its epigenetic editing therapy targeting hepatitis B virus (HBV), following regulatory clearance.

Scholar Rock's Apitegromab Shows Promise in Spinal Muscular Atrophy Trial

Scholar Rock's apitegromab met the primary endpoint in a Phase 3 trial for spinal muscular atrophy (SMA), demonstrating improved muscle function compared to placebo.
The company plans to submit a regulatory application in the first quarter of next year based on the positive trial results.

Roche's Subcutaneous Tecentriq Approved; Gilead's HIV Shot Shows Promise

The FDA approved Roche's Tecentriq Hybreza, the first checkpoint inhibitor available as a subcutaneous injection, offering a faster administration time of about seven minutes.
Gilead's twice-yearly lenacapavir HIV shot reduced infection risk by 96% in a Phase 3 trial, leading to halted trial and plans for regulatory filings and a potential 2025 launch.

Roivant Launches Pulmovant with In-Licensed Bayer Drug for Pulmonary Hypertension

Roivant Sciences has launched Pulmovant, a new venture focused on developing mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, was in-licensed from Bayer for $14 million upfront, with potential milestones reaching $280 million.

AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Reference News

[1]
Five biotech news stories you need to read today
statnews.com · Sep 10, 2024

Roivant acquires mosliciguat from Bayer for pulmonary hypertension; Viridian's thyroid eye disease treatment succeeds in...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy